血管紧张素受体阻滞剂与β受体阻滞剂治疗马凡综合征:随机试验的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入7项随机试验共1442例马凡综合征患者,比较血管紧张素受体阻滞剂(ARB)与对照、ARB与β受体阻滞剂对主动脉根部Z评分年变化率的影响。中位随访3年,ARB使主动脉根部Z评分年增长约减半,β受体阻滞剂效果与ARB相似,间接比较β受体阻滞剂与对照的差异为-0.09(95%CI -0.18至0.00;p=0.042)。
要点
- ARB较对照约减半主动脉根部Z评分年增长率(绝对差-0.07,95%CI -0.12至-0.01;p=0.012)。
- ARB与β受体阻滞剂对主动脉根部Z评分年变化率的影响相似(绝对差0.03,95%CI -0.05至0.10;p=0.48)。
- 间接比较β受体阻滞剂与对照的Z评分年变化差异为-0.09(95%CI -0.18至0.00;p=0.042)。
核心结论
- 在无既往主动脉手术的马凡综合征患者中,ARB使主动脉根部Z评分年增长率约减半,包括正在使用β受体阻滞剂者。
- β受体阻滞剂的效果与ARB相似。
- 假设效应可叠加,从诊断时起联合使用ARB和β受体阻滞剂可能比任一单药治疗更大幅度降低主动脉扩张速率,若维持多年,预期可延迟需要主动脉手术的时间。
研究设计与样本
- 个体患者数据荟萃分析,系统检索MEDLINE、Embase和CENTRAL自建库至2021年11月2日的随机试验。
- 纳入标准为ARB与对照或ARB与β受体阻滞剂的随机比较,使用无既往主动脉手术患者的个体数据。
- 共纳入7项试验、1442例 eligible 患者;其中4项试验676例比较ARB与对照,3项试验766例比较ARB与β受体阻滞剂。
- 主要终点为Valsalva窦处经体表面积校正的主动脉根部尺寸Z评分的年变化率。
主要发现
- ARB与对照比较:中位随访3年,主动脉根部Z评分年均增长ARB组0.07(SE 0.02) vs 对照组0.13(SE 0.02),绝对差-0.07(95%CI -0.12至-0.01;p=0.012)。
- 预设亚组分析显示,ARB效应在FBN1致病变异携带者中尤其大(异质性p=0.0050),且无证据表明ARB效应随β受体阻滞剂使用而变化(异质性p=0.54)。
- ARB与β受体阻滞剂比较:中位随访3年,主动脉根部Z评分年变化ARB组-0.08(SE 0.03) vs β受体阻滞剂组-0.11(SE 0.02),绝对差0.03(95%CI -0.05至0.10;p=0.48)。
- 间接比较:β受体阻滞剂与对照的Z评分年变化差异为-0.09(95%CI -0.18至0.00;p=0.042)。
临床怎么用
- 作者认为,对于无既往主动脉手术的马凡综合征患者,ARB可降低主动脉根部Z评分增长率约一半,包括正在使用β受体阻滞剂者。
- 作者认为,β受体阻滞剂的效果与ARB相似。
- 作者假设效应可叠加,提出从诊断时起联合使用ARB和β受体阻滞剂可能比任一单药治疗更大幅度降低主动脉扩张速率,若维持多年,预期可延迟需要主动脉手术的时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiotensin receptor blockers (ARBs) and β blockers are widely used in the treatment of Marfan syndrome to try to reduce the rate of progressive aortic root enlargement characteristic of this condition, but their separate and joint effects are uncertain. We aimed to determine these effects in a collaborative individual patient data meta-analysis of randomised trials of these treatments. METHODS: In this meta-analysis, we identified relevant trials of patients with Marfan syndrome by systematically searching MEDLINE, Embase, and CENTRAL from database inception to Nov 2, 2021. Trials were eligible if they involved a randomised comparison of an ARB versus control or an ARB versus β blocker. We used individual patient data from patients with no prior aortic surgery to estimate the effects of: ARB versus control (placebo or open control); ARB versus β blocker; and indirectly, β blocker versus control. The primary endpoint was the annual rate of change of body surface area-adjusted aortic root dimension Z score, measured at the sinuses of Valsalva. FINDINGS: We identified ten potentially eligible trials including 1836 patients from our search, from which seven trials and 1442 patients were eligible for inclusion in our main analyses. Four trials involving 676 eligible participants compared ARB with control. During a median follow-up of 3 years, allocation to ARB approximately halved the annual rate of change in the aortic root Z score (mean annual increase 0·07 [SE 0·02] ARB vs 0·13 [SE 0·02] control; absolute difference -0·07 [95% CI -0·12 to -0·01]; p=0·012). Prespecified secondary subgroup analyses showed that the effects of ARB were particularly large in those with pathogenic variants in fibrillin-1, compared with those without such variants (heterogeneity p=0·0050), and there was no evidence to suggest that the effect of ARB varied with β-blocker use (heterogeneity p=0·54). Three trials involving 766 eligible participants compared ARBs with β blockers. During a median follow-up of 3 years, the annual change in the aortic root Z score was similar in the two groups (annual increase -0·08 [SE 0·03] in ARB groups vs -0·11 [SE 0·02] in β-blocker groups; absolute difference 0·03 [95% CI -0·05 to 0·10]; p=0·48). Thus, indirectly, the difference in the annual change in the aortic root Z score between β blockers and control was -0·09 (95% CI -0·18 to 0·00; p=0·042). INTERPRETATION: In people with Marfan syndrome and no previous aortic surgery, ARBs reduced the rate of increase of the aortic root Z score by about one half, including among those taking a β blocker. The effects of β blockers were similar to those of ARBs. Assuming additivity, combination therapy with both ARBs and β blockers from the time of diagnosis would provide even greater reductions in the rate of aortic enlargement than either treatment alone, which, if maintained over a number of years, would be expected to lead to a delay in the need for aortic surgery. FUNDING: Marfan Foundation, the Oxford British Heart Foundation Centre for Research Excellence, and the UK Medical Research Council.
引用
- Pitcher A, Spata E, Emberson J, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022. PMID: 36049495. doi:10.1016/S0140-6736(22)01534-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。